[pubmed] Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis

Intégration des publications parues sur PUBMED
Répondre
Avatar de l’utilisateur

Auteur du sujet
RSS-Bot
Ami(e) d'Argent
Ami(e) d'Argent
Messages : 99
Inscription : 31 mai 2020 09:57
    unknown unknown
Zodiaque :
Âge : 20

[pubmed] Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis

Message par RSS-Bot »


Vitturi BK, et al. Neurol Sci 2020.

ABSTRACT

BACKGROUND: Recent medical advances have enabled the control of neurological symptoms and increased survival of patients with myasthenia gravis (MG). However, MG has many veiled consequences that may be underestimated by neurologists. Our aim was to clarify the social, professional, and neuropsychiatric issues of MG patients.

METHODS: We carried out a cross-sectional cohort study with MG patients from a university-affiliated referral hospital. We registered clinical and sociodemographic data, and patients were classified according the MGFA classification. Clinical severity was assessed with Myasthenia Gravis Composite (MGC) scale. Trained and blind investigators analyzed social and professional outcomes. Neuropsychiatric symptoms were evaluated with the Hospital Anxiety and Depression Scale (HADS) and the social support with the Multidimensional Scale of Perceived Social Support (MSPSS).

RESULTS: We enrolled 49 patients with MG. The mean age was 45.3 ± 18.1 years and 39 (79.6%) were women. There were 19 (38.8%) patients who become unemployed, 23 (46.9%) who had to retire prematurely, 31 (63.3%) that reported a significant reduction in work performance, and 23 (46.9%) who had a reduction in monthly income after the diagnosis of MG. Only 16 (32.6%) received any financial support and 24 (48.9%) patients had the perception of receiving a satisfactory social support. The practice of physical activity is a habit in only 10 patients (20.4%). Neuropsychiatric symptoms were present in 26 (53.1%) patients.

CONCLUSION: Patients with MG are vulnerable to social, professional, and mental disadvantages. Therapeutic success in MG goes beyond symptom relief and inevitably depends on a personalized approach to the patient.

PMID:32592102 | DOI:10.1007/s10072-020-04528-w

Image


Source: https://pubmed.ncbi.nlm.nih.gov/3259210 ... 34&v=2.9.2
Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur association.amis-modo@myasthenie.com


Nous prenons en charge le coût de cette demande (en général +/- USD 40,00$) dans la limite de nos ressources.

Bonne lecture...

Répondre

Revenir à « Echos de la recherche »